within Pharmacolibrary.Drugs.ATC.J;

model J01CA12
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 13.0 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 4000 / 1000000,
    adminCount     = 1,
    Vd             = 0.0144,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Piperacillin is a broad-spectrum β-lactam antibiotic of the ureidopenicillin class. It is commonly used, often in combination with the β-lactamase inhibitor tazobactam, for the treatment of a wide variety of bacterial infections, including respiratory tract infections, urinary tract infections, gastrointestinal infections, and sepsis. Piperacillin is approved and widely used in clinical practice today, particularly in hospital settings.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult subjects following intravenous administration.</p><h4>References</h4><ol><li><p>Maneerot, T, et al., &amp; Pattharachayakul, S (2025). Pharmacokinetics of intravenous piperacillin/tazobactam among patients with peritoneal dialysis-associated peritonitis. <i>Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis</i> 45(1) 57–61. DOI:<a href=&quot;https://doi.org/10.1177/08968608241241449&quot;>10.1177/08968608241241449</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38666694/&quot;>https://pubmed.ncbi.nlm.nih.gov/38666694</a></p></li><li><p>Dulhunty, JM, et al., &amp; Lipman, J (2024). Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis: The BLING III Randomized Clinical Trial. <i>JAMA</i> 332(8) 629–637. DOI:<a href=&quot;https://doi.org/10.1001/jama.2024.9779&quot;>10.1001/jama.2024.9779</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38864155/&quot;>https://pubmed.ncbi.nlm.nih.gov/38864155</a></p></li><li><p>Jumpertz, M, et al., &amp; Cassir, N (2022). Subcutaneously administered antibiotics: a review. <i>The Journal of antimicrobial chemotherapy</i> 78(1) 1–7. DOI:<a href=&quot;https://doi.org/10.1093/jac/dkac383&quot;>10.1093/jac/dkac383</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36374566/&quot;>https://pubmed.ncbi.nlm.nih.gov/36374566</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J01CA12;
